Floatz logo

Ciprofol

Gastric Ulcer

RenJi HospitalSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Gastric Ulcer cohort.

Asset / SponsorPhaseRating
PROPOFOL
RenJi Hospital
Phase 4BB
Indocyanine Green
University Health Network, Toronto
Phase 4BB

Same molecule, other indications

Ciprofol is also rated in:

gastrointestinal polypDormant
BB
Indicative ·
69 / 100
View asset →
gastric cancerDormant
B
Indicative ·
58 / 100
View asset →
intestinal polypDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →